- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05017675
Effect of Dietary SFA and Fructose on Hepatic Insulin Sensitivity
Comparing the Effect of a High SFA Diet and High Fructose Diet on Hepatic Insulin Sensitivity
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale: High rates of de novo lipogenesis (DNL) and high saturated fatty acid (SFA) fraction in the liver both have been associated with poor metabolic health and hepatic insulin resistance. Interestingly, the end product of DNL is mainly SFA. So far it is unknown whether it is the process of DNL or the accumulation of SFA per se that leads to hepatic insulin resistance. This is a clinically relevant question, as it will give novel insights towards the best strategy for prevention and treatment of hepatic insulin resistance. Therefore, it is of interest to compare the effect of a diet that modifies directly hepatic SFA content (high SFA diet) and a diet that changes SFA indirectly by modifying rates of DNL (high fructose diet).
Objective: To determine the effect of a 4-week high SFA diet compared to a 4-week high fructose diet on hepatic insulin sensitivity, on hepatic SFA fraction and DNL.
Study design: This is a randomized intervention study comparing the effects of a 4-week high SFA diet compared to a 4-week high fructose diet on hepatic insulin sensitivity.
Study population: 24 overweight/obese, but otherwise healthy, males and females (BMI 27-38 kg/m2), 45-75 years, will participate in the study. Of these 24 included participants, 18 are expected to meet the study criteria and take part in the measurements following the screening, of these 14 need to complete the study.
Intervention: Participants follow a 4-week high SFA diet and a 4-week high fructose diet.
Main study parameters/endpoints: The primary outcome is hepatic insulin sensitivity (suppression of EGP during clamp) upon a 4-week high SFA diet versus a 4-week fructose diet. Secondary outcomes are DNL upon 4-week high SFA versus 4-week high fructose, and delta (baseline-end intervention) hepatic SFA fraction upon 4-week high SFA versus 4-week high fructose.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Vera Schrauwen-Hinderling, Dr
- Phone Number: 0031 43 3875149
- Email: v.schrauwen@maastrichtuniversity.nl
Study Contact Backup
- Name: Kay Roumans
- Phone Number: 0031 43 3882124
- Email: k.roumans@maastrichtuniversity.nl
Study Locations
-
-
Limburg
-
Maastricht, Limburg, Netherlands, 6229 ER
- Recruiting
- Maastricht University Medical Center
-
Contact:
- Vera Schrauwen-Hinderling, Dr
- Phone Number: 0031 43 3875149
- Email: v.schrauwen@maastrichtuniversity.nl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants are able to provide signed and dated written informed consent prior to any study specific procedures
- Participants should have suitable veins for cannulation or repeated venipuncture
- Women are post-menopausal (defined as at least 1 year post cessation of menses)
- Aged ≥ 45 and ≤ 75 years
- Body mass index (BMI) 27 - 38 kg/m2
- Stable dietary habits (no weight loss or gain >5kg in the past 3 months)
- Sedentary lifestyle (not more than 2 hours of sports per week)
- No signs of active cardiovascular disease, liver or kidney malfunction
- Liver fat content ≥ 2% weight/weight.
Exclusion Criteria:
- Type 2 diabetes
- Previous enrolment in a clinical study with an investigational product during the last 3 months or as judged by the Investigator
- Patients with congestive heart failure and and/or severe renal and or liver insufficiency or another condition that may interfere with outcomes measured in this study.
- Any contra-indication MRI scanning
- Alcohol consumption of >2 servings per day for men and >1 servings per day for woman
- Smoking in the past 6 months
- Men: Hb <8.4 mmol/L, Women: Hb <7.8 mmol/l
- Vegetarian, vegan, food intolerant to common foods (e.g. gluten intolerant, lactose intolerant)
- Medication use that may influence outcome parameters
A medical doctor will judge participation eligibility based on the medical history questionnaire, medication use and fasting blood parameters. If the medical doctor advises that a volunteer cannot participate, the volunteer will be excluded from enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High fructose diet
Participants will receive dietary products high in fructose for 4 weeks.
|
4 week high fructose diet. Intended composition (En%): Carbohydrates: 60-70 Fat: 20-30 Protein: 10-15 Fructose: 20 SFA: 5 |
Experimental: High saturated fat diet
Participants will receive dietary products high in saturated fat for 4 weeks.
|
4 week high saturated fat diet. Intended composition (En%): Carbohydrates: 35-45 Fat: 40-50 Protein: 10-15 Fructose: 5 SFA: 20 |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hepatic insulin sensitivity measured by hyperinsulinemic-euglycemic clamp.
Time Frame: after 28 days of each diet
|
difference in EGP suppression after the high SFA diet and the high fructose diet
|
after 28 days of each diet
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hepatic fat composition measured by proton magnetic resonance spectroscopy
Time Frame: first day of each diet - after 28 days of each diet
|
The change in liver fat composition (%SFA, %MUFA and %PUFA) after the high SFA diet and the high fructose diet
|
first day of each diet - after 28 days of each diet
|
De novo lipogenesis measured by deuterated water
Time Frame: after 25 days of each diet
|
Difference between overnight DNL after the high SFA diet and the high fructose diet.
Measured as relative contribution of newly synthesized palmitate in the VLDL-TG pool expressed as %DNL.
|
after 25 days of each diet
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Liver fat content measured by proton magnetic resonance spectroscopy
Time Frame: after 28 days of each diet
|
Difference in liver fat content after the high SFA diet and the high fructose diet
|
after 28 days of each diet
|
Peripheral and whole-body Insulin sensitivity measured by hyperinsulinemic-euglycemic clamp
Time Frame: after 28 days of each diet
|
Whole body insulin sensitivity is measured as GIR in μmol/kg/min and peripheral insulin sensitivity is measured as Rd in μmol/kg/min.
Difference in GIR and Rd after the high SFA diet and the high fructose diet will be determined
|
after 28 days of each diet
|
Fat oxidation measured by indirect calorimetry
Time Frame: after 25 and 28 days of each diet
|
Fat oxidation as determined by indirect calorimetry, will be compared between the high SFA and high fructose diet
|
after 25 and 28 days of each diet
|
Carbohydrate oxidation measured by indirect calorimetry
Time Frame: after 25 and 28 days of each diet
|
Carbohydrate oxidation as determined by indirect calorimetry will be compared between the high SFA and high fructose diet
|
after 25 and 28 days of each diet
|
Sleeping metabolic rate measured by indirect calorimetry
Time Frame: after 25 days of each diet
|
Sleeping metabolic rate as determined by indirect calorimetry will be compared between the high SFA and high fructose diet
|
after 25 days of each diet
|
Body composition measured by BodPod
Time Frame: day 1
|
Body composition is measured using the BodPod technique and percentage fat mass will be determined for participant characterization.
|
day 1
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL78281.068.21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insulin Resistance
-
Washington University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...CompletedEndoplasmic Reticulum Stress | HIV Related Insulin Resistance | Protease Inhibitor Related Insulin ResistanceUnited States
-
Paloma Almeda-ValdésCompleted
-
German Diabetes CenterYale UniversityRecruiting
-
National Institute of Diabetes and Digestive and...Active, not recruitingSevere Insulin ResistanceUnited States
-
Eunice Kennedy Shriver National Institute of Child...Completed
-
Assiut UniversityCompleted
-
National Taiwan UniversityNational Cheng-Kung University HospitalCompletedExercise, Insulin Resistance, Visceral Adipose TissueTaiwan
-
The University of Texas Medical Branch, GalvestonCompletedInsulin Resistance, DiabetesUnited States
-
University Health Network, TorontoCompletedInsulin Resistance, DiabetesCanada
-
University Health Network, TorontoCompletedInsulin Resistance Syndrome X | Pancreatic Beta Cell FunctionCanada
Clinical Trials on High fructose diet
-
University of DelawareRecruitingInflammation | Blood PressureUnited States
-
University of LausanneCentre Hospitalier Universitaire VaudoisCompleted
-
Rockefeller UniversityRobert C. Atkins Foundation; The Rogosin InstituteCompletedEnd-stage Renal DiseaseUnited States
-
Washington University School of MedicineCompleted
-
University of California, DavisNational Heart, Lung, and Blood Institute (NHLBI); University of Southern California and other collaboratorsCompletedObesity | Type 2 Diabetes | Chronic Disease of Cardiovascular SystemUnited States
-
John SievenpiperCanadian Diabetes Association; The Physicians' Services Incorporated Foundation and other collaboratorsUnknownObesity | Overweight | Body Weight | Adiposity | Obesity, AbdominalCanada
-
University of TorontoCanadian Institutes of Health Research (CIHR); Canadian Diabetes Association; The Physicians' Services Incorporated FoundationUnknownCardiovascular Diseases | Stroke | Hypertension | Diabetes Mellitus, Type 2 | Gout | Metabolic Syndrome XCanada
-
Touro University, CaliforniaRecruitingInsulin Resistance | Insulin Sensitivity | Pre DiabetesUnited States
-
Federal University of Rio Grande do SulCompletedSedentary Lifestyle | Dyslipidemias | Lipid Metabolism Disorders | Carbohydrate Inducible Hyperlipemia
-
University of Missouri-ColumbiaCompletedInsulin Sensitivity | Insulin ToleranceUnited States